Has Plexus (PLXS) Finally Turned the Corner After Recent Q4 Earnings

Key Takeaways

• Plexus (PLXS) delivered a Q4 CY2025 that largely met revenue expectations and beat adjusted EPS estimates, signaling a potential inflection point for the electronic manufacturing services provider.
• Strong program ramps in Healthcare/Life Sciences and Aerospace/Defense, coupled with strategic investments in automation, are driving an upgraded outlook for fiscal 2026.
• Despite recent stock appreciation and a "Buy" consensus, valuation metrics like a P/E of 32.64 suggest the market has already priced in much of this anticipated growth, warranting careful consideration.

Has Plexus (PLXS) Finally Turned the Corner After Recent Q4 Earnings?

Plexus Corp. (NASDAQ: PLXS), a key player in the electronic manufacturing services (EMS) sector, recently reported its fiscal first quarter 2026 financial results, following a strong Q4 CY2025 performance that has investors buzzing. While the company's Q4 CY2025 revenue of $1.07 billion was in line with Wall Street estimates, its adjusted EPS of $1.78 comfortably beat consensus expectations of $1.73, marking a 2.7% positive surprise. This beat, coupled with robust guidance for Q1 CY2026, has fueled optimism, pushing shares higher.

The market's reaction has been notably positive, with the stock currently trading at $215.59, up significantly from the $195.27 reported shortly after earnings. This surge reflects investor confidence in Plexus's ability to execute on its growth strategy, particularly in its key market sectors. However, it's worth noting that while Plexus has seen an impressive 52% increase in its stock price over the past six months, its year-over-year performance of 0.9% still lags behind the broader Electronic Manufacturing Services industry's growth of 112.5% over the same period.

Management's forward-looking statements further bolstered sentiment. For the fiscal first quarter 2026, Plexus anticipates revenues between $1.05 billion and $1.09 billion, with the midpoint of $1.07 billion aligning with analyst expectations. More importantly, the company's adjusted EPS guidance for Q1 CY2026, set at $1.88 at the midpoint, exceeded analyst estimates of $1.76, indicating sustained profitability momentum. This upgraded outlook suggests that the underlying business drivers are strengthening, positioning Plexus for continued growth.

The company's ability to consistently meet or exceed earnings expectations, even with revenue largely in line, speaks to its operational discipline. This is a critical factor for investors in a cyclical industry like EMS, where efficiency and cost management can significantly impact the bottom line. The focus now shifts to whether Plexus can maintain this trajectory and close the performance gap with its industry peers.

What's Driving Plexus's Growth and Profitability?

Plexus's recent performance isn't just about hitting numbers; it's rooted in strategic execution and strong demand in specific market segments. A significant driver has been the successful ramp-up of new manufacturing programs, with 28 wins in the fiscal fourth quarter alone, projected to contribute an impressive $274 million in annualized revenues once fully operational. This robust pipeline underscores the company's ability to secure new business and expand its market share.

The growth narrative is particularly strong in the Healthcare/Life Sciences and Aerospace/Defense sectors. CEO Todd Kelsey highlighted that these segments are experiencing robust growth, contributing significantly to the overall revenue increase. While revenues from the Americas region saw a healthy 9.4% increase to $336 million, the EMEA and Asia-Pacific regions experienced declines of 7% and 2.1% respectively, indicating a mixed geographical performance that bears watching.

Beyond new business, operational efficiency is a core pillar of Plexus's strategy. The company is heavily investing in automation and AI-driven processes, including warehouse robotics and machine learning for production optimization. These initiatives are designed to deliver both margin improvement and capital spending efficiencies, shifting investment towards technology rather than new plant construction. This focus on leveraging existing capacity with advanced tools is crucial for maintaining competitiveness and driving profitability in the long term.

Furthermore, management credited improved demand in semiconductors and energy markets as contributing factors to the positive results. The company's diversified customer base, with its top 10 customers accounting for 49% of net revenues, provides a degree of stability, though it also means a concentration risk that investors should acknowledge. CFO Patrick Jermain emphasized that margin expansion will depend on balancing these automation investments with ongoing productivity improvements, aiming for significant operating profit expansion and robust free cash flow.

How Do Plexus's Financials Stack Up?

A deeper dive into Plexus's financial health reveals a company with solid fundamentals, though some areas warrant closer scrutiny. As of September 27, 2025, Plexus boasted cash and cash equivalents of $307 million, a healthy increase from $237.6 million in June 2025. This strong cash position provides flexibility for strategic investments and managing working capital. The company also maintains a manageable long-term debt of $91.9 million, indicating a prudent approach to leverage.

Looking at the trailing twelve months (TTM), Plexus's profitability metrics present a mixed picture. The gross margin stands at 10.0%, with an operating margin of 5.1% and a net margin of 4.3%. While these margins are respectable for the EMS industry, the operating margin contracted by 40 basis points to 5.8% in the fiscal fourth quarter compared to the prior year. This slight compression suggests that while revenue is growing, the cost of sales or operating expenses are rising proportionally, or even slightly faster.

Cash flow generation remains a highlight. Cash flows from operations were a robust $132 million for the quarter, leading to a free cash flow of $97.2 million. For fiscal 2025, free cash flow came in at $154 million. This strong free cash flow allows Plexus to return capital to shareholders, as evidenced by the repurchase of $21.5 million worth of shares at an average price of $134.07 per share during the quarter. For the full fiscal year 2025, share repurchases totaled $65 million, with $85 million remaining under the current $100 million authorization.

However, some TTM growth figures raise questions. While net income surged by 54.6% and EPS by 56.1% year-over-year for fiscal 2025, operating cash flow declined by 42.9% and free cash flow by 54.9%. This divergence between strong earnings growth and declining cash flow from operations and free cash flow suggests potential working capital pressures or changes in accounting for non-cash items. Investors should monitor this trend closely, as sustainable growth typically requires robust cash generation.

What Are the Key Risks and Opportunities for PLXS Investors?

Investing in Plexus, despite its recent positive momentum, comes with a distinct set of risks and opportunities that investors must weigh carefully. On the opportunity side, the company's robust program pipeline and market share gains in high-growth sectors like Healthcare/Life Sciences and Aerospace/Defense are significant tailwinds. The shift towards automation and AI-driven processes promises long-term margin expansion and capital efficiency, reducing reliance on new facility construction. Management's upgraded outlook for fiscal 2026, projecting revenue growth towards the 9% to 12% target, underscores confidence in these drivers.

Furthermore, Plexus's strong balance sheet, characterized by a healthy cash position and low debt-to-equity ratio of 0.15, provides financial stability and flexibility. The company's commitment to returning capital to shareholders through share buybacks is also a positive signal, demonstrating confidence in its intrinsic value. The diversified customer base, while concentrated at the top, helps mitigate risks associated with any single client.

However, several risks loom. The EMS industry is inherently cyclical and sensitive to global economic conditions. While the Americas region is performing well, declines in EMEA and Asia-Pacific revenues highlight geographical vulnerabilities. Supply chain pressures, though proactively managed by Plexus, remain a persistent concern across the manufacturing sector, potentially impacting program execution and working capital demands. The company's ability to navigate these external headwinds will be crucial.

Valuation also presents a risk. With a current P/E ratio of 32.64 and a P/S of 1.40, Plexus trades at a premium compared to some industry peers, especially considering its TTM revenue growth of 1.8%. While the market is pricing in future growth, any slowdown in program ramps or operational efficiency gains could lead to a re-evaluation. The stock's underperformance relative to the broader Electronic Manufacturing Services industry over the past year also suggests that it faces competitive pressures or has unique challenges to overcome.

Is Plexus (PLXS) a Buy, Hold, or Sell at Current Levels?

Considering Plexus's recent performance and future outlook, the consensus among analysts leans towards a "Buy," with a total of 4 analysts covering the stock. Notably, Benchmark's David Williams reiterated a "Strong Buy" rating with a price target of $220 as recently as March 16, 2026, implying a modest upside of 1.97% from the current price of $215.59. Needham's James Ricchiuti also maintains a "Strong Buy" with a target of $206, suggesting a slight downside from current levels. Stifel's Ruben Roy, however, holds a "Hold" rating with a price target of $200. The average analyst price target stands at $194.00, indicating a potential downside of -10.08% from the current trading price.

This divergence in price targets, particularly the average target being below the current stock price, suggests that while the operational story is strong, the market may have already priced in much of the anticipated upside. The stock has surged significantly, hitting a 52-week high of $217.50 recently, and is trading near the top of its $103.43 – $217.50 range. This rapid appreciation, coupled with a P/E ratio of 32.64, indicates a rich valuation, especially when compared to its TTM revenue growth of 1.8%.

For investors, the decision hinges on whether Plexus can not only meet but consistently exceed its upgraded growth and profitability targets. The company's strategic investments in automation and AI, coupled with a robust program pipeline, offer a compelling long-term narrative. However, the current valuation demands flawless execution and sustained acceleration in revenue and free cash flow generation. Any misstep or unexpected macroeconomic headwind could lead to a correction.

Given the current trading price near its 52-week high and the average analyst price target suggesting a potential pullback, a "Hold" rating seems appropriate for existing investors. For those looking to initiate a position, waiting for a more attractive entry point or clearer signs of sustained, accelerating growth and margin expansion might be a more prudent strategy. The story is positive, but the price reflects much of that optimism already.

Plexus has demonstrated strong operational execution and an upgraded outlook, but its current valuation demands careful consideration. Investors should monitor program ramp-ups, the impact of automation on margins, and the company's ability to navigate supply chain dynamics for future signals.

Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.